NEOG — Neogen Corporation stock price, charts and financials

QT76Neogen Corporation

Neogen Corporation (NASDAQ: NEOG) is a Healthcare company in the Medical - Diagnostics & Research industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
11.81
-0.09-0.76%
NEOGQT76Neogen Corporation·NASDAQ
11.81-0.76%
TA
Loading chart...
Signal & projected range
Earnings big beat — drift (PEAD)Historical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
Snapshot
Index-P/E-EPS (ttm)-0.03Insider Own3.26%Shs Outstand217.67MPerf Week28.51%
Market Cap2.57BForward P/E28.80EPS next Y0.41Insider Trans0.00%Shs Float216.50MPerf Month24.19%
Enterprise Value3.18BPEG-EPS next Q0.05Inst Own-Short Float4.98%Perf Quarter29.92%
Income-8.00MP/S2.95EPS this Y1077.77%Inst Trans-Short Ratio4.76Perf Half Y15.22%
Sales870.00MP/B1.23EPS next Y39.77%ROA-0.24%Short Interest10.79MPerf YTD68.96%
Book/sh9.62P/C13.82EPS next 5Y16.48%ROE-0.37%52W High12.85 -8.09%Perf Year153.43%
Cash/sh0.85P/FCF51.06EPS past 3/5Y-ROIC-0.65%52W Low4.63 155.08%Perf 3Y-48.85%
Dividend Est.-EV/EBITDA23.03Sales past 3/5Y1.91% 13.20%Gross Margin44.29%Volatility8.36% 4.61%Perf 5Y-72.65%
Dividend TTM-EV/Sales3.65EPS Y/Y TTM99.40%Oper. Margin-2.48%ATR (14)0.55Perf 10Y-42.19%
Dividend Ex-Date-Quick Ratio2.91Sales Y/Y TTM-2.79%Profit Margin-0.91%RSI (14)71.58Recom2.73
Dividend Gr. 3/5Y-Current Ratio3.82EPS Q/Q-10.00%SMA2016.63%Beta1.75Target Price13.00
Payout0.00%Debt/Eq0.00Sales Q/Q0.00%SMA5023.82%Rel Volume1.37Prev Close11.90
Employees2,974LT Debt/Eq0.43EarningsOct 08SMA20035.23%Avg Volume2.31MPrice11.81
IPO DateAug 23, 1989Option/ShortYes / YesEPS/Sales Surpr.58.82% 6.10%Net Debt/EBITDA4.39Volume3,163,727Change-0.76%
Analyst Ratings
DateActionAnalystRatingTarget
Aug-03-26ReiteratedPiper SandlerNeutral$11$13
Jan-12-26ReiteratedPiper SandlerNeutral$6.50$10
Jan-09-26ReiteratedGuggenheimBuy$12
Dec-10-25UpgradeCJS SecuritiesMarket PerformMarket Outperform
Oct-16-25ReiteratedPiper SandlerNeutral$5.00$6.50
Jul-29-25DowngradeWilliam BlairOutperformMarket Perform
Apr-22-25ReiteratedPiper SandlerNeutral$18$5.00
Aug-06-24ReiteratedPiper SandlerNeutral$17$18
Nov-22-22UpgradeWilliam BlairMarket PerformOutperform
Mar-19-19UpgradeCraig-HallumHoldBuy
Latest News
Jul-31-26
Jul-30-26
Jul-28-26
Jul-20-26
Jul-17-26
Jun-27-26
Jun-27-2609:41AM
Company

Neogen Corporation, including its affiliated companies, is a global leader in creating, manufacturing, and distributing a wide range of products crucial for maintaining food quality and animal health. The enterprise is structured into two primary divisions: Food Safety and Animal Safety. The Food Safety segment delivers advanced diagnostic test kits and associated solutions to identify detrimental or unintended contaminants in food and animal feed. This extensive detection capability covers threats such as foodborne pathogens, spoilage-causing organisms, naturally occurring toxins, food allergens, genetically modified ingredients, ruminant by-products, specific meat identification, residual drugs and pesticides, and overall sanitation issues. A key product is the AccuPoint Advanced rapid sanitation test, which quickly spots adenosine triphosphate (ATP), indicating the presence of living cells, to verify cleanliness. Customers for this segment are diverse, encompassing producers and processors of food and feed, grain operations, manufacturers of processed foods like cookies, crackers, candy, and ice cream, as well as those handling meat, poultry, seafood, fruits, vegetables, and dairy. It also serves laboratories and producers of pharmaceuticals, cosmetics, and veterinary vaccines. The Animal Safety division provides a comprehensive portfolio for the animal health market. Offerings include veterinary instruments, pharmaceuticals, vaccines, topical medications, parasiticides, diagnostic products, rodenticides, cleaning agents, disinfectants, insecticides, and genomics testing services. This segment also supplies specialized products for researchers investigating biologically active substances. Its immunoassay test kits are vital for detecting illicit and therapeutic drugs in farm and racing animals, identifying drug residues in meat and meat products, and assisting in human forensic toxicology drug screenings. Moreover, products from this division are instrumental in upholding hygienic conditions and minimizing the risks posed by bacteria, fungi, and viruses. Neogen Corporation was established in 1981 and is headquartered in Lansing, Michigan.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
FY 2026
5/31/2026
FY 2025
5/31/2025
FY 2024
5/31/2024
FY 2023
5/31/2023
FY 2022
5/31/2022
FY 2021
5/31/2021
FY 2020
5/31/2020
FY 2019
5/31/2019
Total Revenue870870895924822527468418414
Cost of Goods Sold Incl. D&A485462473462416284253222222
Gross Profit386409421463406243215196192
Selling, General and Administrative Excl. Other412412402383342167125114111
Research and Development191821222617161513
Other Operating Expense-240-11-2000000
Operating Income-21-229773859746868
Interest Expense31-587273560000
Unusual Expense
Non-Operating Income (Expense)45-44-1,071-18-42155
Net Income Before Taxes-7-8-1,133-14-2260757273
Income Taxes00-41-5112141313
Consolidated Net Income-8-8-1,092-9-2348615960
Net Income From Continuing Operations-8-8-1,092-9-2348615960
Net Income-8-8-1,092-9-2348615960
EPS (Recurring)-0.03-0.04-5.03-0.04-0.120.450.570.570.58
EPS (Basic, Before Extraordinaries)-0.03-0.04-5.03-0.04-0.120.450.570.570.58
EPS (Diluted)-0.03-0.04-5.03-0.04-0.120.450.570.560.57
EBITDA138-22-93818312284969191
Other After Tax Adjustments
Stock Option Compensation Expense
Price To Earnings Ratio58.8080.9663.5949.42
Price To Sales Ratio2.962.251.423.074.025.4210.458.957.08
Gross Margin44.3747.0147.0450.1149.3946.1145.9446.8946.38
Operating Margin-2.41-2.531.018.334.6211.2015.8116.2716.43
Net Margin-0.92-0.92-122.01-0.97-2.809.1113.0314.1114.49
Shares Outstanding218218217216189108106105104
Market Capitalization2,5751,9551,2722,8403,3062,8584,8923,7392,930
Operating Lease Expense
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$13.15$10.75$8.34$5.94$3.54 Close Price0.00K0.38K0.76K1.14K1.52KUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Rocklin Amy MFormer Chief Legal OfficerMay 18 '26Option Exercise9.2935,183326,85092,423May 19
Moylan John PatrickChief Accounting OfficerMay 04 '26Option Exercise9.534,55843,43818,905May 05
Nassif MikhealCEOFeb 17 '26Buy10.9423252704Feb 17
Nassif MikhealCEOFeb 02 '26Buy10.0024240681Feb 02
Nassif MikhealCEOJan 26 '26Buy9.8625246657Feb 02
Nassif MikhealCEOJan 16 '26Buy9.331371,279632Jan 16
Naemura David H.Former CFODec 01 '25Option Exercise5.9812,91277,21493,936Dec 02
Nassif MikhealCEONov 03 '25Buy6.251771,106495Nov 07
BOREL JAMES CDirectorOct 27 '25Option Exercise6.193,80223,53596,347Oct 29
CAPELLO JEFFREY DDirectorOct 27 '25Option Exercise6.193,80223,53532,502Oct 29
Green Ronald DDirectorOct 27 '25Option Exercise6.191,77711,00018,654Oct 29
Gupta AashimaDirectorOct 27 '25Option Exercise6.191,77711,00027,790Oct 29
RODRIGUEZ RAFAEL ADirectorOct 27 '25Option Exercise6.191,77711,00020,821Oct 28
Tobin James PDirectorOct 27 '25Option Exercise6.191,77711,00043,347Oct 28
Woteki Catherine EDirectorOct 27 '25Option Exercise6.191,77711,00019,117Oct 28
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.